Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Cyclophosphamide 345Rituximab 310Vincristine 160Doxorubicin 157venetoclax 156fludarabine 153Specimen Handling 152Prednisone 152Biopsy 122obinutuzumab 117Magnetic Resonance Spectroscopy 117Lenalidomide 111Dexamethasone 106Cytarabine 100ibrutinib 96Etoposide 94fludarabine phosphate 87Methotrexate 86acalabrutinib 80zanubrutinib 73Bendamustine Hydrochloride 73pembrolizumab 63blinatumomab 63CT-P10 61Gemcitabine 52glofitamab 45Nivolumab 45Calcium Dobesilate 45Mercaptopurine 44prednylidene 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sra protein, Drosophila × Lymphoid × 1 year × Clear all
NCT07464210 2026-03-11

Nemtabrutinib, Bortezomib, and Rituximab for WM

Seoul National University Hospital

Phase 2 Not yet recruiting
19 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡